-->

Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMar 4, 2008View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2008View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 4, 2008View HTMLDownload DOCDownload PDF
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 28, 2008View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 27, 2008View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventFeb 26, 2008View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 22, 2008View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2008View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2008View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2008View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2008View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2008View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2008View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Feb 8, 2008View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJan 31, 2008Download DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 23, 2008View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJan 22, 2008View HTMLDownload DOCDownload PDF
CORRESPCorrespondence from the Filer to the SECJan 18, 2008View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECJan 10, 2008View HTMLDownload DOCDownload PDFDownload XLS
5Annual filing director officer or owner of more than ten percent.Jan 10, 2008View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Jan 10, 2008View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Jan 10, 2008View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJan 4, 2008View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECJan 3, 2008View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 3, 2008View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-150      151-152

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information